Back to discover
Disease
Lymphoma, Follicular
Late-stage therapeutic developmentEmerging researchSteady momentum
4
Publications
19
Clinical trials
1
Related conditions
12
Associated genes
7
Related proteins
2024
Latest publication
Current focus
B-lymphocyte cd20 biologyPhosphatidylinositol 4 biologyTherapeutic developmentInflammation & immunity
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B
Clinical trial2026-10-08Status changed to Terminated · ClinicalTrials.gov
Clinical trial2026-10-07Results posted · ClinicalTrials.gov
Clinical trial2026-10-01Status changed to Active, not recruiting · ClinicalTrials.gov
Clinical trial2026-09-11Status changed to Active, not recruiting · ClinicalTrials.gov
Clinical trial2026-08-28Status changed to Active, not recruiting · ClinicalTrials.gov
Clinical trial2026-08-04Status changed to Active, not recruiting · ClinicalTrials.gov
B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.
Research2024-10-11International journal of molecular sciences
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 1 clinical trial expected to report results, the earliest in Q3 2030.
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20302026-10-15
Major clinical milestoneImportant
Primary completion2026-06-19
Clinical MilestonesViewHide
Results expected
Regulatory UpdatesViewHide
- 2026-02-16Product authorisation ended — DuvelisibCopiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.
Activity timeline3
- 2026-10-15ClinicalA Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin LymphomaResults expected Q3 2030
- 2026-06-19ClinicalA Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaPrimary completion
- 2026-02-16RegulatoryProduct authorisation ended — DuvelisibCopiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Duvelisibapproved
Product authorisation ended — Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or… (2026)
Ibritumomab tiuxetanapproved
Product authorisation ended — Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation… (2024)
Odronextamabapproved
Conditional marketing authorisation — Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or… (2024)
Epcoritamabapproved
Conditional marketing authorisation — Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)
Lisocabtagene maraleucelapproved
Original application approval — Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymph… (2022)
Mosunetuzumabapproved
Conditional marketing authorisation — Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or… (2022)
Lenalidomideapproved
Generic approval — Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatme… (2021)
Zanubrutinibapproved
Original application approval — Brukinsa as monotherapy is indicated for the treatment of adult patients with Walden… (2021)
Dimethyl fumarateapproved
Generic approval — Multiple myeloma Lenalidomide Mylan as monotherapy is indicated for the maintenance treat… (2020)
Rituximabapproved
Biosimilar approval — Ruxience is indicated in adults for the following indications: Non?Hodgkin’s lymphoma (NH… (2020)
Axicabtagene ciloleucelapproved
Original application approval — Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymph… (2018)
Tisagenlecleucelapproved
Original application approval — Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to an… (2018)
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
7
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2024emaConditional marketing authorisation — Odronextamab· Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy. source ↗
2023emaConditional marketing authorisation — Epcoritamab· Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. source ↗
2022emaConditional marketing authorisation — Mosunetuzumab· Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. source ↗
Product approvals and authorisations
2022emaOriginal application approval — Lisocabtagene maraleucel· Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. source ↗
2021emaOriginal application approval — Zanubrutinib· Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). Brukinsa in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. source ↗
2021emaGeneric approval — Lenalidomide· Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). source ↗
2020emaGeneric approval — Dimethyl fumarate· Multiple myeloma Lenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphoma Lenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a). source ↗
2020emaBiosimilar approval — Rituximab· Ruxience is indicated in adults for the following indications: Non?Hodgkin’s lymphoma (NHL) Ruxience is indicated for the treatment of previously untreated patients with stage III?IV follicular lymphoma in combination with chemotherapy. Ruxience maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. Ruxience monotherapy is indicated for treatment of patients with stage III?IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Ruxience is indicated for the treatment of patients with CD20 positive diffuse large B cell non?Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Chronic lymphocytic leukaemia (CLL) Ruxience in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy. Rheumatoid arthritis Ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease?modifying anti?rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies. Ruxience has been shown to reduce the rate of progression of joint damage as measured by X?ray and to improve physical function, when given in combination with methotrexate. Granulomatosis with polyangiitis and microscopic polyangiitis Ruxience, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA). Pemphigus vulgaris Ruxience is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). source ↗
2018emaGeneric approval — Lenalidomide· Multiple myelomaLenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). source ↗
2018emaOriginal application approval — Axicabtagene ciloleucel· Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. source ↗
2018emaOriginal application approval — Tisagenlecleucel· Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. source ↗
Other regulatory activity
2026emaProduct authorisation ended — Duvelisib· Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. source ↗
2024emaProduct authorisation ended — Ibritumomab tiuxetan· Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
Most influential
Recent publications
Major themes5
- Genomics1
- Germinal Center1
- Lymphoma, Follicular1
- Proto-Oncogene Proteins c-bcl-61
- Software1
Leading journals4
- American journal of hematology1
- Genome research1
- International journal of molecular sciences1
- The Lancet. Oncology1
Leading researchers8
- Almohaisen FLJ1
- Bartlett NL1
- Birol I1
- Bot A1
- Braunschweig I1
- Chavez JC1
- Connors J1
- Deol A1
Affiliations (unnormalised)6
- Dana-Farber Cancer Institute2
- Banner MD Anderson Cancer Center1
- Canada's Michael Smith Genome Sciences Center1
- City of Hope National Medical Center1
- Cleveland Clinic Foundation1
- Colorado Blood Cancer Institute1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
B-lymphocyte antigen CD20via MS4A10.62Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformvia PIK3CD0.59T-cell surface glycoprotein CD3 epsilon chainvia CD3E0.58Protein cereblonvia CRBN0.57B-lymphocyte antigen CD19via CD190.54Histone-lysine N-methyltransferase EZH2via EZH20.52B-cell receptor CD22via CD220.30
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.